CIK 0000730272 · Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 042729386
- Phone
- 7814499560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-15 | Mhatre Rohin Director | Grant or award | +973 | 4,019 | ||
| 2025-05-15 | Mhatre Rohin Director | Grant or award · Stock Option (Right to Buy) | +1,800 | 1,800 | ||
| 2025-05-15 | Hunt Anthony Director | Sale 10b5-1 | −2,043 | $122.66 | $251K | 134,258 |
| 2025-05-15 | Hunt Anthony Director | Sale 10b5-1 | −17,596 | $123.57 | $2.2M | 116,662 |
| 2025-05-15 | Hunt Anthony Director | Sale 10b5-1 | −6,533 | $124.34 | $812K | 110,129 |
| 2025-05-15 | Hunt Anthony Director | Sale 10b5-1 | −268 | $125.20 | $34K | 109,861 |
| 2025-05-15 | Hunt Anthony Director | Sale 10b5-1 | −7 | $127.00 | $889 | 109,854 |
| 2025-04-01 | Bylund James Chief Operating Officer | Shares withheld for taxes | −454 | $128.50 | $58K | 23,711 |
| 2025-03-17 | Hunt Anthony Director | Option exercise 10b5-1 | +5,000 | $33.87 | $169K | 141,301 |
| 2025-03-17 | Hunt Anthony Director | Option exercise 10b5-1 | +21,756 | $59.52 | $1.3M | 163,057 |
| 2025-03-17 | Hunt Anthony Director | Sale 10b5-1 | −60 | $148.05 | $9K | 162,997 |
| 2025-03-17 | Hunt Anthony Director | Sale 10b5-1 | −100 | $150.38 | $15K | 162,897 |
| 2025-03-17 | Hunt Anthony Director | Sale 10b5-1 | −2,518 | $151.09 | $380K | 160,379 |
| 2025-03-17 | Hunt Anthony Director | Sale 10b5-1 | −6,176 | $151.96 | $939K | 154,203 |
| 2025-03-17 | Hunt Anthony Director | Sale 10b5-1 | −15,619 | $152.82 | $2.4M | 138,584 |
| 2025-03-17 | Hunt Anthony Director | Sale 10b5-1 | −2,283 | $153.70 | $351K | 136,301 |
| 2025-03-17 | Hunt Anthony Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 202,344 | ||
| 2025-03-17 | Hunt Anthony Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −21,756 | 0 | ||
| 2025-03-17 | Pax Margaret Director | Purchase | +250 | $150.69 | $38K | 1,043 |
| 2025-03-13 | Bylund James Chief Operating Officer | Grant or award | +381 | 24,340 |
Page 7 of 11 · 215 trades